Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ERID-KSOPR-0037/2023 | Other Identifier | Institute of Oncology Ljubljana - KSOPR (Commission for Scientific Review of Research Protocols) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This interventional study evaluates the late endocrine and metabolic consequences of treatment of primary brain tumors in childhood. Childhood brain tumor survivors are at increased risk of developing long-term complications such as hormonal deficiencies, obesity, impaired growth, dyslipidemia, and other metabolic disorders, which may significantly affect long-term health and quality of life.
The aim of this study is to assess the prevalence and severity of endocrine and metabolic late effects in patients treated for brain tumors during childhood in Slovenia, and to identify associations with tumor localization, treatment modality, and physical performance.
Participants undergo structured clinical follow-up examinations and targeted endocrine and metabolic assessments according to the study protocol. The results of this study may help identify individuals at increased risk and improve long-term follow-up strategies, prevention, and management of late treatment-related complications.
This is a prospective interventional clinical study designed to evaluate the prevalence and severity of late endocrine and metabolic complications in survivors of primary brain tumors treated during childhood. Advances in pediatric oncology have improved survival, but many patients develop long-term health consequences that require systematic monitoring and early management.
The study includes patients who were treated for primary brain tumors during childhood and are followed at the Institute of Oncology Ljubljana. Participants undergo standardized clinical assessments as part of the study intervention, including evaluation of endocrine function, metabolic status, and physical competence. The study aims to determine the occurrence of late endocrine and metabolic disorders and to assess the relationship between these complications and clinical factors such as tumor localization, treatment modality (surgery, radiotherapy, chemotherapy), and overall functional status.
The primary objectives are:
to assess the prevalence of endocrine disorders (e.g., growth hormone deficiency, thyroid dysfunction, gonadal dysfunction, adrenal insufficiency) after childhood brain tumor treatment,
to evaluate metabolic consequences including obesity, dyslipidemia, insulin resistance, and other metabolic abnormalities,
to analyze associations between late effects and tumor localization, treatment characteristics, and physical competence of the participants.
The study is expected to provide important national data regarding late endocrine and metabolic outcomes in childhood brain tumor survivors in Slovenia and contribute to identification of patients at higher risk. The results may support development of improved follow-up protocols and preventive strategies, as well as timely referral for appropriate endocrine and metabolic treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Late Effects Assessment Group | Experimental | Participants treated for primary brain tumors in childhood undergo a structured follow-up assessment to evaluate late endocrine and metabolic complications. The study includes clinical examination, anthropometric measurements, laboratory endocrine and metabolic testing, and evaluation of physical competence. Outcomes are analyzed in relation to tumor location and previous treatment modalities. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Endocrine and Metabolic Late Effects Assessment | Diagnostic Test | Participants undergo a structured endocrine and metabolic follow-up assessment after childhood brain tumor treatment. The intervention includes clinical examination, anthropometric measurements (height, weight, BMI), laboratory endocrine testing (pituitary and thyroid function, adrenal axis, gonadal hormones), metabolic testing (glucose and lipid profile), and evaluation of physical competence. The aim is to identify late endocrine and metabolic complications and assess their association with tumor location and previous treatment modalities. |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of Endocrine and Metabolic Late Complications | Percentage of participants with at least one endocrine or metabolic late complication, defined as the presence of any endocrine disorder (growth hormone deficiency, hypothyroidism, adrenal insufficiency, hypogonadism) or any metabolic disorder (overweight/obesity defined by body mass index ≥25 kg/m², dyslipidemia defined by abnormal lipid profile, impaired glucose metabolism defined by fasting plasma glucose or HbA1c criteria), assessed by standardized clinical and laboratory evaluation. | During a single assessment visit (up to 1 day) |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of Endocrine Disorders | Percentage of participants diagnosed with at least one endocrine disorder (growth hormone deficiency, hypothyroidism, adrenal insufficiency, hypogonadism) based on hormonal laboratory testing and clinical evaluation. | During a single assessment visit (up to 1 day) |
| Prevalence of Metabolic Disorders |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Oncology Ljubljana | Ljubljana | 1000 | Slovenia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Participants who were treated for primary brain tumors in childhood undergo standardized endocrine and metabolic evaluation during follow-up, including clinical examination, laboratory testing, and assessment of physical competence, in order to identify late endocrine and metabolic complications and associated risk factors.
Not provided
Not provided
Not provided
Not provided
|
Percentage of participants diagnosed with at least one metabolic disorder (overweight/obesity defined by body mass index ≥25 kg/m², dyslipidemia defined by abnormal lipid profile, impaired glucose metabolism defined by fasting plasma glucose or HbA1c criteria). |
| During a single assessment visit (up to 1 day) |
| Association Between Tumor Location and Endocrine Disorders | Odds ratio (OR) for the presence (yes/no) of endocrine disorders according to tumor location, estimated using logistic regression analysis. Results will be reported as odds ratios (unitless) with 95% confidence intervals. | During a single assessment visit (up to 1 day) |
| Body Mass Index (BMI) | Body mass index (BMI) calculated as weight in kilograms divided by height in meters squared (kg/m²). Weight and height are measured during the same assessment visit and combined to calculate BMI as a single outcome value. | During a single assessment visit (up to 1 day) |
| Fasting Plasma Glucose | Fasting plasma glucose concentration measured using standard laboratory methods. | During a single assessment visit (up to 1 day) |
| LDL Cholesterol | Low-density lipoprotein (LDL) cholesterol concentration measured using standard laboratory methods. | During a single assessment visit (up to 1 day) |
| Physical Competence | Distance covered during a 6-minute walk test performed according to a standardized protocol, reported in meters (m). | During a single assessment visit (up to 1 day) |